ACADIA Initiates Phase II Trial with Pimavanserin for Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals (NASDAQ: ACAD ) today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for